About the session

Next-generation sequencing (NGS) tests encompassing multi-gene panels, whole-exome (WES), and whole-genome sequencing (WGS) are becoming an integral part of clinical diagnostics for hereditary cancers. However, analyzing and interpreting these panels can be incredibly time-consuming and complex.

Join Dr. Ana Krivokuca as she presents a use-case of how the Institute for Oncology and Radiology Serbia (IORS), a National Cancer Research Center, uses QCI Interpret, a clinical decision support software, in their NGS testing pipeline to annotate, assess, and interpret the clinical significance of germline variants in hereditary cancers.

Attendees will:

  • Explore the challenges of variant classification, including the limitations of manual curation, handling of VUS, and incorporating guideline recommendations.
  • Learn how the IORS uses QCI Interpret to evaluate genomic profiles of hereditary cancers and identify variants with clinical utility.
  • Receive a demonstration of how QCI Interpret filters and prioritizes variants, transparently computes ACMG/AMP classifications, and auto-generates clinical reports with the latest evidence.


Ana Krivokuca
Institute for Oncology and Radiology of Serbia
Dr. Ana Krivokuca is the founder and the Head of the Department for genetic counseling at the Institute for Oncology and Radiology of Serbia. An experienced clinical laboratory geneticist, Dr. Krivokuca specializes in the interpretation of genomic data, variant annotation, and genetic counseling. Currently, her research is focused on genetics and molecular biomarkers in breast and ovarian cancers. She completed her Ph.D. studies in Genetics from the University of Belgrade and her Masters in Bioethics from Clarkson University and Mount Sinai Hospital in New York. To date, Dr. Krivokuca has published over 40 peer-reviewed papers and leads numerous research grants.